Breast Cancer Clinical Trials in Houston, Texas

76 studies are recruiting for breast cancer in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

   The purpose of this study is to provide prospective evidence that the use of Magseed/Sentimag in marking axillary lymph nodes and guiding surgical localization in patients with breast cancer following neo-adjuvant chemotherapy (NAC) is effective.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Baylor Medicine, Houston, Texas

   Locations

   2 in total

   Run by

   Endomagnetics Ltd.

   See if you can join NCT03796559 on ClinicalTrials.gov

2. Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

   This trial studies how well fecal microbiota transplantation works in treating diarrhea or colitis (inflammation of the intestines) that is caused by certain types of medications (called immune-checkpoint inhibitors) in patients with genitourinary cancer. Fecal microbiota transplantation may effect…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT04038619 on ClinicalTrials.gov

3. Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

   This is a multicenter, multi-arm, biomarker-stratified trial designed to evaluate biomarker-directed therapies in patients with estrogen receptor-positive/hormone receptor-negative (ER+/HR-) and triple-negative (TN) metastatic breast cancer (MBC). The trial integrates both retrospective and prospec…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Baylor College of Medicine, Houston, Texas

   Locations

   6 in total

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT07340541 on ClinicalTrials.gov

4. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

   This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   90 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06172478 on ClinicalTrials.gov

5. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   20 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

6. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

7. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

   The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Oncology Consultants, P.A., Houston, Texas

   Locations

   567 in total

   Run by

   Stemline Therapeutics, Inc.

   See if you can join NCT06492616 on ClinicalTrials.gov

8. A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

   This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Houston, Texas

   Locations

   67 in total

   Run by

   AstraZeneca

   See if you can join NCT05123482 on ClinicalTrials.gov

9. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Oncology Consultants, Houston, Texas

   Locations

   26 in total

   Run by

   SystImmune Inc.

   See if you can join NCT06293898 on ClinicalTrials.gov

10. Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

    Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn: * About the safety of the study treatments and if people toler…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Houston Methodist Hospital ( Site 0022), Houston, Texas

    Locations

    17 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT06797635 on ClinicalTrials.gov

11. A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

    AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be re…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UT MD Anderson, Houston, Texas

    Locations

    7 in total

    Run by

    Angiex, Inc.

    See if you can join NCT06440005 on ClinicalTrials.gov

12. A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

    The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) an…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    50 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT05307705 on ClinicalTrials.gov

13. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Houston Methodist Hospital Cancer Center, Houston, Texas

    Locations

    231 in total

    Run by

    Relay Therapeutics, Inc.

    See if you can join NCT06982521 on ClinicalTrials.gov

14. Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

    For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later. A way to find these cells is by looking for tiny bits of cancer DNA that are …

    Stage

    Not phased

    Ages

    18 to 99

    Site

    UT Health Houston, Houston, Texas

    Locations

    16 in total

    Run by

    Tempus AI

    See if you can join NCT07211178 on ClinicalTrials.gov

15. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

    Stage

    Phase 3

    Ages

    18 to 60

    Site

    Lyndon Baines Johnson General Hospital, Houston, Texas

    Locations

    1261 in total

    Run by

    NRG Oncology

    See if you can join NCT05879926 on ClinicalTrials.gov

16. Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer

    To learn about the effects of shorter RNI regimens in patients with breast cance who have had a lumpectomy or mastectomy and who are at higher risk for lower risk for the disease returning.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    The University of Texas M. D. Anderson Cancer Center, Houston, Texas

    Locations

    5 in total

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT07076485 on ClinicalTrials.gov

17. FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

    This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    M. D. Anderson Cancer Center, Houston, Texas

    Locations

    5 in total

    Run by

    Fate Therapeutics

    See if you can join NCT07216105 on ClinicalTrials.gov

18. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Houston, Texas

    Locations

    23 in total

    Run by

    AstraZeneca

    See if you can join NCT05877599 on ClinicalTrials.gov

19. A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

    A study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Research Site, Houston, Texas

    Locations

    40 in total

    Run by

    AstraZeneca

    See if you can join NCT07205822 on ClinicalTrials.gov

20. TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

    The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HE…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Baylor College of Medicine, Houston, Texas

    Locations

    11 in total

    Run by

    Ana C Garrido-Castro, MD

    See if you can join NCT06533826 on ClinicalTrials.gov

21. Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

    To find a recommended dose of the combination of alpelisib and pembrolizumab that can be given to patients with metastatic breast cancer or melanoma.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06545682 on ClinicalTrials.gov

22. A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

    The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Texas Oncology Gulf Coast, Houston, Texas

    Locations

    35 in total

    Run by

    Jazz Pharmaceuticals

    See if you can join NCT07102381 on ClinicalTrials.gov

23. A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

    This is a Phase 2, single-site, single-arm open-label trial of zanidatamab in patients with early stage, low risk HER2+ BC. The primary objective is to determine the efficacy of zanidatamab for patients with early stage HER2/neu positive (HER2+) breast cancer (BC) as determined by pathologic comple…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05035836 on ClinicalTrials.gov

24. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

    This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson, Houston, Texas

    Locations

    14 in total

    Run by

    NextCure, Inc.

    See if you can join NCT06774963 on ClinicalTrials.gov

25. A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

    This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inop…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Research Site, Houston, Texas

    Locations

    320 in total

    Run by

    AstraZeneca

    See if you can join NCT06103864 on ClinicalTrials.gov